AI-based target and drug discovery licensing deals reached $47.1 billion in the first half of 2026 alone, according to deal-tracking firm DealForma — already surpassing the $44.6 billion recorded across the entirety of 2025. The figure captures just how aggressively pharmaceutical companies have embraced AI drug discovery partnerships, even as a striking fact remains true as of October 2026: no drug discovered or designed primarily through artificial intelligence has yet received full approval from the US Food and Drug Administration.
Where the money is going
The deal total reflects a wave of partnerships struck throughout 2026 between major pharmaceutical companies and AI-native biotechs, including AstraZeneca’s roughly $1.5 billion to $1.86 billion partnership with insitro, Eli Lilly’s up to $2.75 billion deal with Insilico Medicine, and GSK and Pfizer’s separate licensing arrangements with Chai Discovery — each representing a different pharmaceutical giant’s bet on a different AI drug discovery approach, from target identification to generative molecule design to protein structure prediction.
The gap between capital and clinical proof
The disconnect between enormous deal values and the absence of any fully approved AI-discovered drug highlights a structural reality of pharmaceutical development: even AI-accelerated candidate identification still requires candidates to clear the same multi-year, multi-phase clinical trial process that has always governed drug approval, and that process has not been meaningfully shortened by AI’s involvement in earlier discovery stages. Several AI-discovered candidates are currently progressing through various phases of clinical trials, meaning the industry’s first approval is likely still at least a few years away even under optimistic timelines.
Why investors and pharma executives remain bullish anyway
Despite the absence of an approved AI-discovered drug, pharmaceutical executives have continued committing capital to AI partnerships on the theory that even modest improvements in candidate selection quality — identifying drugs more likely to succeed in clinical trials, or ruling out poor candidates earlier before expensive trial costs are incurred — could generate enormous value given how expensive and failure-prone traditional drug development has historically been. Industry estimates have long put the average cost of bringing a new drug to market in the billions of dollars, with the vast majority of that cost tied to clinical trial failures rather than successes.
The skeptics’ case
Critics of the current AI drug discovery enthusiasm argue that the sector may be experiencing a dealmaking bubble disconnected from demonstrated clinical results, pointing out that AI biotech companies have strong incentives to publicize partnership deal values — often representing maximum potential milestone payments rather than guaranteed near-term cash — while clinical trial failure rates for AI-discovered candidates remain largely unproven relative to traditional drug discovery methods. Some biotech investors have drawn comparisons to prior hype cycles in biotech, where promising early-stage technology attracted enormous capital before clinical validation caught up, sometimes with disappointing results.
The counter-argument from AI drug discovery proponents
Supporters respond that judging AI drug discovery’s success solely by whether an approved drug exists yet is premature, given that most AI-native drug discovery companies only began operating in earnest within the past five to eight years — a timeline shorter than the typical decade-plus drug development cycle even for a successful candidate. From this view, the current wave of clinical trials involving AI-discovered candidates represents the field’s first real test, with meaningful readouts expected over the next two to four years rather than immediately.
What it means next
The $47.1 billion first-half 2026 figure all but guarantees 2026 will be the largest year yet for AI drug discovery dealmaking, intensifying pressure on the sector to finally produce a clinical success story that validates the capital already committed. Whichever AI-discovered candidate reaches FDA approval first — whenever that occurs — will likely be treated as a landmark moment for the industry, shaping investor and pharma executive appetite for the next wave of AI drug discovery partnerships that follows.
Photo: Towfiqu barbhuiya / PEXELS via Pexels
